Hot Life Sciences Companies To Buy For 2014

With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.

T = Trends for a Stock’s Movement

Corning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.

Samsung Electronics���(SSNLF.PK)�purchase of Corning shares and a glass supply agreement between the two companies will last until 2023. Samsung Display is buying $2.3 billion worth of shares in Corning, according to a statement from Corning, making Samsung�� combined stake in Corning 7.4 percent. The Samsung purchase is expected to close in the first quarter of 2014.

10 Best Industrial Disributor Stocks To Buy For 2015: Intrepid Potash Inc (IPI)

Intrepid Potash, Inc.( Intrepid), incorporated on November 19, 2007, is a producer of muriate of potash (potassium chloride or potash) in the United States and are engaged the production and marketing of potash and langbeinite (sulfate of potash magnesia), another mineral containing potassium, magnesium, and sulfate, that is produced from langbeinite ore and as Trio when it refers to sales and marketing. Its Carlsbad assets consist of underground mining operations, which are supported by surface processing facilities. It is also operators of solar solution mining operations, as its Moab and Wendover facilities both utilize these techniques for recovering potash. Its revenues are generated from the sale of potash and Trio. As of December 31, 2011, the Company owned five potash production facilities, three in New Mexico and two in Utah. Its two products are potash and langbeinite, which is marketed as Trio.

Potash

The Company derives revenues and gross margin are derived from the production and sales of potash. Its potash is marketed for sale into three primary markets: the agricultural market as a fertilizer, the industrial market as a component in drilling and fracturing fluids for oil and gas wells, and the animal feed market as a nutrient. Its sales of potash tend to focus on agricultural areas and feed manufacturers in central and western United States, as well as oil and gas drilling areas in the Rocky Mountains and the greater Permian Basin area.

Trio

Trio is marketed into two primary markets, the agricultural market as a fertilizer and the animal feed market as a nutrient. It markets Trio internationally through an exclusive marketing agreement with PCS Sales (USA), Inc. (PCS Sales) for sales outside the United States and Canada and through a non-exclusive agreement for sales into Mexico.

Advisors' Opinion:

• [By Paul Quintaro]

  Nocella initiated coverage on the following stocks:

  Mosaic (NYSE: MOS) - Outperform, $57 price target - The analyst is attracted to a recent trend toward "improving demand in the potash and phosphate markets" and an expectation for "substantial" returns to holders over the next few years. Nocella noted the company's solid position in the phosphate market which could "better position Mosaic if others are interested in its potash assets." Agrium (NYSE: AGU) - Outperform, $122 target - Called Agrium's input business "the most diverse, vertically integrated" within the Ag space. Sees "a clear path to strong earnings growth from both its Retail and Wholesale" units which could translate to "robust cash flows with lower volatility." Potash (NYSE: POT) - Market Perform, $37 target. CF Industries (NYSE: CF) - Market Perform, $235 target. Interpid Potash (NYSE: IPI) - Market Perform, $16 target.

  Also impacting the Ag names Wednesday is headlines out of CF the company is working with investment banks related to an MLP.

• [By Ben Levisohn]

  Potash Corp of Saskatchewan (POT), for instance, lost 16% last year, while Mosaic (MOS) dropped 15%, Intrepid Potash (IPI) plunged 26% and Agrium (AGU) declined 5.9%.

Hot Life Sciences Companies To Buy For 2014: Perry Ellis International Inc.(PERY)

Perry Ellis International, Inc. engages in designing, sourcing, marketing, and licensing apparel products for men and women in the United States and internationally. The company?s men?s wear offerings include casual sportswear and bottoms, dress shirts and pants, jeans wear, golf apparel, sweaters, sports apparel, swimwear and swim accessories, active wear, outerwear and leather accessories. Its women?s wear offerings comprise dresses, sportswear, and swimwear and swim accessories. The company offers its products under the brand names of Perry Ellis, Axis, Tricots St. Raphael, Jantzen, John Henry, Cubavera, the Havanera Co., Centro, Solero, Natural Issue, Munsingwear, Grand Slam, Original Penguin, Mondo di Marco, Redsand, Pro Player, Manhattan, Axist, Savane, Farah, Gotcha, Girl Star, MCD, Laundry by Shelli Segal, C&C California, Ben Hogan, and Rafaella. It also licenses the Nike brand for swimwear and swimwear accessories; the JAG brand for men?s and women?s swimwear and cover-ups; the Callaway Golf brand and Top-Flite for golf apparel; the PGA TOUR brand, including Champions Tour for golf apparel; and Pierre Cardin for men?s sportswear. The company distributes its products primarily to wholesale customers, including department stores, national and regional chain stores, mass merchants, specialty stores, sporting goods stores, the corporate wear market, and e-commerce, as well as clubs and independent retailers. As of March 2, 2011, it operated 38 Perry Ellis and 3 Original Penguin retail outlet stores primarily in upscale retail outlet malls across the United States and Puerto Rico; 1 Perry Ellis and 1 Cubavera retail store in Miami, Florida; and 7 Original Penguin retail stores in upscale demographic markets in the United States. The company was formerly known as Supreme International Corporation and changed its name to Perry Ellis International, Inc. in June 1999. Perry Ellis International, Inc. was founded in 1967 and is headquarte red in Miami, Florida.

Advisors' Opinion:

• [By Lauren Pollock]

  Perry Ellis International Inc.(PERY) cut its outlook for the fiscal year, citing weakness in its third quarter. The clothing company said revenue was hurt by reduced shipments, primarily due to the reduction of private-label business for the mid-tier channel, as well as reduced sales through its direct retail channel. Shares fell.

• [By , Zacks Investment Research]

  Estimates have come down after disappointing fourth quarter preliminary results for Perry Ellis (PERY), sending this apparel maker to a Zacks Rank # 5 (Strong Sell) last month.

• [By Adem Tahiri]

  Perry Ellis International (NASDAQ: PERY  ) is an apparel company that designs, markets, and licenses its brand-name products. The stock has dropped by nearly half this year, and it has sparked the interest of many value investors. Last Thursday, fourth-quarter earnings results beat lowered expectations and gave the stock a small bump.�

• [By Ben Levisohn]

  Perry Ellis International�(PERY) has dropped 20% to $12.60 in pre-open trading after the apparel company blamed bad weather for slashing its full year guidance in less than half.

Hot Life Sciences Companies To Buy For 2014: Customers Bancorp Inc (CUBI)

Customers Bancorp, Inc. (Customers Bancorp), incorporated in April 2010, through its wholly owned subsidiary Customers Bank (the Bank), provides financial products and services to small businesses, not-for-profits and consumers through its fourteen branches in Southeastern Pennsylvania (Bucks, Berks, Chester and Delaware Counties), Rye, New York (Westchester County) and Hamilton, New Jersey (Mercer County). Customers Bank also provides liquidity to the mortgage market worldwide through the operation of its mortgage warehouse business. As of December 31, 2011, Customers Bancorp had total assets of $2.08 billion, including net loans (including held for sale loans) of $1.50 billion, total deposits of $1.58 billion. The Company offers a range of banking products and financial services to its commercial and consumer customers in Suburban Philadelphia, Pennsylvania, Central New Jersey and Southeastern New York. It offers a range of lending products to cater to its customers��needs, including small business loans, mortgage warehouse loans, multi-family and commercial real estate loans, residential mortgage loans and consumer loans. It also offers traditional depository products, including commercial and consumer checking accounts, non-interest-bearing demand accounts, money market deposit accounts, savings accounts and time deposit accounts and cash management services. On September 17, 2011, Customers Bank became a wholly owned subsidiary of Customers Bancorp. On September 17, 2011, Customers Bancorp acquired Berkshire Bancorp, Inc. and its subsidiary Berkshire Bank. In May 2013, Customers Bancorp Inc merged with CMS Bancorp Inc.

Lending Activities

The Company focuses its lending efforts to the lending areas, such as commercial lending, which includes business, small business and multi-family and commercial real estate lending; specialty Lending, which include warehouse lending, and consumer lending, which include local market mortgage lending and home equity lending. It also pr! ovide warehouse financing worldwide and multi-family lending in the Mid-Atlantic States.

The Bank�� commercial lending is segmented into three groups, which include multi-family and commercial real estate, business banking and small business banking. The small business banking platform originates loans, including small business administration loans, through the branch network sales force and a team of dedicated small business relationship managers. During the year ended December 31, 2011, it originated and closed $121.5 million of multi-family loans commitments. As of December 31, 2011, it had $536.9 million in commercial loans outstanding, comprising approximately 35.3% of its total loan portfolio (which includes loans held for sale). During 2011, it originated and closed $167.7 million of commercial loans and commitments. As of December 31, 2011, loans in its warehouse lending portfolio, as well as loans held for sale totaled $794.3 million outstanding, comprising approximately 52.3% of its total loan portfolio (which includes loans held for sale). During the year ended December 31, 2011, it funded $7.7 billion of mortgage loans under warehouse facilities.

The Company offers a range of deposit products to its customers, including checking accounts, savings accounts, money market accounts and other deposit accounts, including fixed-rate, fixed-maturity retail time deposits ranging in terms from 30 days to five years, individual retirement accounts, and non-retail time deposits consisting of jumbo certificates greater than or equal to $100,000. As of December 31, 2011, its deposit portfolio was consisted of 54.9% of core deposits. Its financial products include Internet banking, wire transfers, electronic bill payment, lock box services, remote deposit capture services, courier services, merchant processing services, cash vault, controlled disbursements, positive pay and cash management services (including account reconciliation, collections and sweep accounts).

! Sources o! f Fund

The Company offers a range of deposit accounts, including checking, savings, money market and time deposits. Deposits are obtained primarily from its service area. As of December 31, 2011, the total deposits grew to $1.58 billion.

Investment Activities

The Company�� investment securities portfolio consists of United States Treasury, government agency and mortgage-backed securities (guaranteed by an agency of the United States government and non-agency guaranteed), municipal securities, domestic corporate debt, and asset-backed securities. In addition to generating revenue, it maintains the investment portfolio to manage interest rate risk, provide liquidity, provide collateral for other borrowings and diversify the credit risk of earning assets. As of December 31, 2011, $79.1 million of its investment securities were classified as available for sale (AFS). As of December 31, 2011, the fair value of its investment securities portfolio was approximately $409.9 million. As of December 31, 2011, it held $319.5 million of investment securities that were classified as held to maturity (HTM).

Advisors' Opinion:

• [By Rich Smith]

  Wyomissing, Pa.-based Customers Bancorp (NASDAQ: CUBI  ) has a new CFO.

  On Tuesday, Customers Bancorp announced that Interim Chief Financial Officer James D. Hogan�intends to retire from the bank on Aug. 13. Replacing Hogan will be Robert E. Wahlman, a new hire from Doral Financial, who will join Customers initially in the post of executive vice president on Aug. 5, and then be promoted to permanent CFO on the 13th.

Hot Life Sciences Companies To Buy For 2014: Glatfelter (GLT)

P. H. Glatfelter Company manufactures and sells specialty papers and fiber-based engineered materials in the United States and internationally. It offers carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; book publishing papers for the production of hardbound books and other book publishing needs; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, playing card, and other niche specialty applications. The company also provides food and beverage paper used for tea bags and single serve coffee products; metallized products used in the labeling of beer bottles, innerliners, gift wrap, self-adhesive labels, and other consumer products applications; and composite laminates papers used in production of decorative laminates, furniture, and flooring applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. In addition, it offers airlaid non-woven fabric-like materials used in feminine hygiene products, adult incontinence products, cleaning pads and wipes, food pads, napkins and tablecloths, and baby wipes. The company markets its products directly, as well as through wholesale paper merchants, brokers, and agents. P. H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.

Advisors' Opinion:

• [By Marc Bastow]

  Specialty papers and and fiber-based materials manufacturer P.H. Glatfelter (GLT) raised its quarterly dividend 10% to 11 cents per share, payable May 1 to shareholders of record as of April 3.
  GLT Dividend Yield: 1.44%

• [By Eric Volkman]

  Glatfelter (NYSE: GLT  ) has a new asset in its portfolio. The company announced it has finalized the acquisition of Germany-based Dresden Papier, which according to the American firm is "the leading global supplier of nonwoven wallpaper base materials."

• [By CRWE]

  Glatfelter (NYSE:GLT) reported that the previously announced presentation by Dante C. Parrini, Chairman and Chief Executive Officer, at the Deutsche Bank Global Industrials and Basic Materials Conference on Wednesday, June 13, 2012 will be available via a live web cast.

Hot Life Sciences Companies To Buy For 2014: Incitec Pivot Ltd (ICPVY)

Incitec Pivot Limited is engaged in the manufacture, trading and distribution of fertilizers, industrial explosives, and chemicals. It operates in two segments: fertilizers, which include Incitec Pivot Fertilisers(IPF), Southern Cross International (SCI), and Fertilisers Elimination (Elim) and explosives, which includes Dyno Nobel Americas (DNA), Dyno Nobel Asia Pacific (DNAP), and Explosives Eliminations (Elim). IPF manufactures products, such as urea, ammonia and single super phosphate. DNA manufactures and sells industrial explosives and related products and services to the mining, quarrying and construction industries and also manufactures agricultural chemicals. SCI manufactures ammonium phosphates and distributes manufactured fertilizer product to wholesaler. DNAP manufactures industrial explosives and related products and services to the mining industry in the Asia Pacific region. In December 2011, it acquired a 49% interest in Maine Drilling Group. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australian stocks fell early Wednesday, tracking a weak lead from the U.S. but with a few blue-chip miners higher after gains for some commodities overnight. The S&P/ASX 200 (AU:XJO) retreated 0.4% to 5,237.80 after similar losses for the main Wall Street indexes, with the Australian benchmark trading around its lowest level since October. Among the major decliners, Qantas Airways Ltd. (AU:QAN) (QUBSF) lost 2.5%, Harvey Norman Holdings Ltd. (AU:HVN) (HNORY) gave up 1.3%, and Incitec Pivot Ltd. (AU:IPL) (ICPVY) fell 1.8%. Santos Ltd. (AU:STO) (STOSF) fell 2.6% on indication it will miss its lowered production guidance for 2013, according to the Australian Financial Review. On the upside, top miners BHP Billiton Ltd. (AU:BHP) (BHP) and Rio Tinto Ltd. (AU:RIO) (RIO) rose 0.3% and 0.7%, respectively, while Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) traded 1% higher. Shares of global shopping-mall developer Westfield Group Australia (AU:WDC) (WEFIF) were on halt

Hot Life Sciences Companies To Buy For 2014: Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.

MM-398

MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.

The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.

MM-121

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.

MM-111

MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.

MM-302

MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.

MM-151

MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 biopharmaceuticals player that's just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.

  If you take a look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it's now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.

  Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.

  Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�